{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T03:46:47Z","timestamp":1766720807751,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40258-023-00826-4","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:02:47Z","timestamp":1692723767000},"page":"107-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5918-1692","authenticated-orcid":false,"given":"Martin","family":"Vu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7487-2491","authenticated-orcid":false,"given":"Koen","family":"Degeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5206-5111","authenticated-orcid":false,"given":"Ella R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-0022","authenticated-orcid":false,"given":"Piers","family":"Blombery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Westerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5788-5805","authenticated-orcid":false,"given":"Maarten J.","family":"IJzerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"826_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12938-021-00973-6","volume":"21","author":"Y Yao","year":"2022","unstructured":"Yao Y, Lin X, Li F, Jin J, Wang H. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the Global Burden of Disease study 2019. Biomed Eng Online. 2022;21:4. https:\/\/doi.org\/10.1186\/s12938-021-00973-6.","journal-title":"Biomed Eng Online"},{"key":"826_CR2","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.3390\/cancers13133134","volume":"13","author":"L Smolej","year":"2021","unstructured":"Smolej L, Vod\u00e1rek P, \u00c9csiov\u00e1 D, \u0160imkovi\u010d M. Chemoimmunotherapy in the first-line treatment of chronic lymphocytic leukaemia: dead yet, or alive and kicking? Cancers (Basel). 2021;13:3134. https:\/\/doi.org\/10.3390\/cancers13133134.","journal-title":"Cancers (Basel)."},{"key":"826_CR3","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(10)61381-5.","journal-title":"Lancet"},{"key":"826_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"K Fischer","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208\u201315. https:\/\/doi.org\/10.1182\/blood-2015-06-651125.","journal-title":"Blood"},{"key":"826_CR5","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/ajh.24808","volume":"92","author":"J Crombie","year":"2017","unstructured":"Crombie J, Davids MS. IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017;92:1393\u20137. https:\/\/doi.org\/10.1002\/ajh.24808.","journal-title":"Am J Hematol"},{"key":"826_CR6","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","volume":"103","author":"E Campo","year":"2018","unstructured":"Campo E, Cymbalista F, Ghia P, J\u00e4ger U, Pospisilova S, Rosenquist R, et al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018;103:1956\u201368. https:\/\/doi.org\/10.3324\/haematol.2018.187583.","journal-title":"Haematologica"},{"key":"826_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3324\/haematol.2018.207399","volume":"104","author":"ID Giudice","year":"2019","unstructured":"Giudice ID, Fo\u00e0 R. Another step forward in the 20-year history of IGHV mutations in chronic lymphocytic leukemia. Haematologica. 2019;104:219\u201321. https:\/\/doi.org\/10.3324\/haematol.2018.207399.","journal-title":"Haematologica"},{"key":"826_CR8","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1080\/14728222.2020.1832465","volume":"24","author":"R Moia","year":"2020","unstructured":"Moia R, Boggione P, Mahmoud AM, Kodipad AA, Adhinaveni R, Sagiraju S, et al. Targeting p53 in chronic lymphocytic leukemia. Expert Opin Ther Targets. 2020;24:1239\u201350. https:\/\/doi.org\/10.1080\/14728222.2020.1832465.","journal-title":"Expert Opin Ther Targets"},{"key":"826_CR9","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360. https:\/\/doi.org\/10.1182\/blood-2017-09-806398.","journal-title":"Blood"},{"key":"826_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:23\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.019.","journal-title":"Ann Oncol"},{"key":"826_CR11","unstructured":"Abbvie. IMBRUVICA\u00ae (ibrutinib) approved by U.S. FDA for the first-line treatment of chronic lymphocytic leukemia. 2016. https:\/\/news.abbvie.com\/news\/imbruvica-ibrutinib-approved-by-us-fda-for-first-line-treatment-chronic-lymphocytic-leukemia.htm#:~:text=NORTH%20CHICAGO%2C%20Ill.%2C%20March,chronic%20lymphocytic%20leukemia%20(CLL). Accessed 9 Jun 2022."},{"key":"826_CR12","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"J Burger","year":"2015","unstructured":"Burger J, Tedeschi A, Barr P, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1509388.","journal-title":"N Engl J Med"},{"key":"826_CR13","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","volume":"103","author":"PM Barr","year":"2018","unstructured":"Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018;103:1502\u201310. https:\/\/doi.org\/10.3324\/haematol.2018.192328.","journal-title":"Haematologica"},{"key":"826_CR14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787\u201398. https:\/\/doi.org\/10.1038\/s41375-019-0602-x.","journal-title":"Leukemia"},{"key":"826_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","volume":"20","author":"C Moreno","year":"2019","unstructured":"Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:43\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(18)30788-5.","journal-title":"Lancet Oncol"},{"key":"826_CR16","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"T Shanafelt","year":"2019","unstructured":"Shanafelt T, Wang X, Kay N, Hanson C, O\u2019Brien S, Barrientos J, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1817073.","journal-title":"N Engl J Med"},{"key":"826_CR17","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1812836.","journal-title":"N Engl J Med"},{"key":"826_CR18","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1080\/10428194.2022.2084731","volume":"63","author":"DGT Raa","year":"2022","unstructured":"Raa DGT, van der Straten L, van Gelder M, Kersting S, Levin MD, Mous R, et al. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. Leuk Lymphoma. 2022;63:2276\u201389. https:\/\/doi.org\/10.1080\/10428194.2022.2084731.","journal-title":"Leuk Lymphoma"},{"key":"826_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3960\/jslrt.20002","volume":"60","author":"K Kojima","year":"2020","unstructured":"Kojima K, Burger JA. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. J Clin Exp Hematop. 2020;60:130\u20137. https:\/\/doi.org\/10.3960\/jslrt.20002.","journal-title":"J Clin Exp Hematop"},{"key":"826_CR20","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.3390\/curroncol28050326","volume":"28","author":"J Costello","year":"2021","unstructured":"Costello J, Kang M, Banerji V. Frontline treatment of the young, fit patient with CLL: a Canadian perspective. Curr Oncol. 2021;28:3825\u201335. https:\/\/doi.org\/10.3390\/curroncol28050326.","journal-title":"Curr Oncol"},{"key":"826_CR21","unstructured":"Pharmaceutical Benefit Schedule. Ibrutinib: capsule 140 mg; Imbruvica\u00ae. 2020. https:\/\/www.pbs.gov.au\/pbs\/industry\/listing\/elements\/pbac-meetings\/psd\/2019-11\/ibrutinib-capsule-140-mg-imbruvica. Accessed 9 Jun 2022."},{"key":"826_CR22","unstructured":"National Institute for Health and Care Excellence. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation. 2017. https:\/\/www.nice.org.uk\/guidance\/ta429. Accessed 9 Jun 2022."},{"key":"826_CR23","unstructured":"Canadian Agency for Drugs and Technologies in Health. Imbruvica for chronic lymphocytic leukemia (previously untreated)\u2014details. 2016. https:\/\/www.cadth.ca\/imbruvica-chronic-lymphocytic-leukemia-previously-untreated-details. Accessed 9 Jun 2022."},{"key":"826_CR24","unstructured":"Australian Government Department of Health. Guidelines for preparing assessments for the Medical Services Advisory Committee. Canberra: Australian Government Department of Health; 2021."},{"key":"826_CR25","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.18553\/jmcp.2014.20.11.1086","volume":"20","author":"Y Bae","year":"2014","unstructured":"Bae Y, Mullins CD. Do value thresholds for oncology drugs differ from nononcology drugs? J Manag Care Spec Pharm. 2014;20:1086\u201392. https:\/\/doi.org\/10.18553\/jmcp.2014.20.11.1086.","journal-title":"J Manag Care Spec Pharm"},{"key":"826_CR26","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1200\/jco.2010.32.0838","volume":"29","author":"D Gonzalez","year":"2011","unstructured":"Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol. 2011;29:2223\u20139. https:\/\/doi.org\/10.1200\/jco.2010.32.0838.","journal-title":"J Clin Oncol"},{"key":"826_CR27","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","volume":"23","author":"BS Woods","year":"2020","unstructured":"Woods BS, Sideris E, Palmer S, Latimer N, Soares M. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23:1613\u201321. https:\/\/doi.org\/10.1016\/j.jval.2020.08.2094.","journal-title":"Value Health."},{"key":"826_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/jco.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37:269\u201377. https:\/\/doi.org\/10.1200\/jco.18.01580.","journal-title":"J Clin Oncol"},{"key":"826_CR29","unstructured":"R\u00fccker G, Krahn U, K\u00f6nig J, Efthimiou O, Davies A, Papakonstantinou T, et al. netmeta: network meta-analysis using frequentist methods. 2022. https:\/\/cran.r-project.org\/web\/packages\/netmeta\/netmeta.pdf. Accessed 9 Jun 2022."},{"key":"826_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O\u2019Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112\u201320. https:\/\/doi.org\/10.1182\/blood.2021014960.","journal-title":"Blood"},{"key":"826_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"key":"826_CR32","unstructured":"Jackson C, Metcalfe P, Amdahl J, Warkentin M, Kunzmann K. Flexible parametric survival and multi-state models. 2021. https:\/\/cran.r-project.org\/web\/packages\/flexsurv\/flexsurv.pdf. Accessed 9 Jun 2022."},{"key":"826_CR33","unstructured":"University of California, Berkeley and Max Planck Institute for Demographic Research. Human Mortality Database. 2022. www.mortality.org. Accessed 9 Jun 2022."},{"key":"826_CR34","unstructured":"Medicare Benefit Schedule. MBS online downloads. 2022. http:\/\/www.mbsonline.gov.au\/internet\/mbsonline\/publishing.nsf\/Content\/downloads. Accessed 9 June 2022."},{"key":"826_CR35","unstructured":"Pharmaceutical Benefit Schedule. PBS publications archive. 2022. https:\/\/www.pbs.gov.au\/info\/publication\/schedule\/archive. Accessed 9 Jun 2022."},{"key":"826_CR36","unstructured":"Cancer Institute NSW. Cancer treatments online. 2022. https:\/\/www.eviq.org.au\/. Accessed 9 Jun 2022."},{"key":"826_CR37","unstructured":"Independent Hospital Pricing Authority. National Hospital Cost Data Collection, AR-DRG cost weight tables V8.0x, round 21 (financial year 2016\u201317). 2019. https:\/\/www.ihpa.gov.au\/publications\/national-hospital-cost-data-collection-ar-drg-cost-weight-tables-v80x-round-21. Accessed 9 Jun 2022."},{"key":"826_CR38","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3109\/10428194.2011.643405","volume":"53","author":"M-H Lafeuille","year":"2012","unstructured":"Lafeuille M-H, Vekeman F, Wang S-T, Kerrigan M, Menditto L, Duh MS. Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:1146\u201354. https:\/\/doi.org\/10.3109\/10428194.2011.643405.","journal-title":"Leuk Lymphoma"},{"key":"826_CR39","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3109\/10428194.2014.961012","volume":"56","author":"CE Kosmas","year":"2015","unstructured":"Kosmas CE, Shingler SL, Samanta K, Wiesner C, Moss PAH, Becker U, et al. Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival. Leuk Lymphoma. 2015;56:1320\u20136. https:\/\/doi.org\/10.3109\/10428194.2014.961012.","journal-title":"Leuk Lymphoma"},{"key":"826_CR40","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10198-012-0419-2","volume":"14","author":"K Tolley","year":"2013","unstructured":"Tolley K, Goad C, Yi Y, Maroudas P, Haiderali A, Thompson G. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ. 2013;14:749\u201359. https:\/\/doi.org\/10.1007\/s10198-012-0419-2.","journal-title":"Eur J Health Econ"},{"key":"826_CR41","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, et al. Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1713976.","journal-title":"N Engl J Med"},{"key":"826_CR42","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.18553\/jmcp.2021.27.11.1532","volume":"27","author":"A Chatterjee","year":"2021","unstructured":"Chatterjee A, Shapouri S, Manzoor BS, Ravelo A, Sail K, Qendri V, et al. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States. J Manag Care Spec Pharm. 2021;27:1532\u201344. https:\/\/doi.org\/10.18553\/jmcp.2021.27.11.1532.","journal-title":"J Manag Care Spec Pharm"},{"key":"826_CR43","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood.2020004922","volume":"136","author":"KK Patel","year":"2020","unstructured":"Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood. 2020;136:1946\u201355. https:\/\/doi.org\/10.1182\/blood.2020004922.","journal-title":"Blood"},{"key":"826_CR44","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/j.clml.2017.12.005","volume":"18","author":"R Sinha","year":"2018","unstructured":"Sinha R, Redekop WK. Cost-effectiveness of ibrutinib compared with obinutuzumab with chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom. Clin Lymphoma Myeloma Leuk. 2018;18:e131\u201342. https:\/\/doi.org\/10.1016\/j.clml.2017.12.005.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"826_CR45","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/bloodadvances.2017015461","volume":"2","author":"JI Barnes","year":"2018","unstructured":"Barnes JI, Divi V, Begaye A, Wong R, Coutre S, Owens DK, et al. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Adv. 2018;2:1946\u201356. https:\/\/doi.org\/10.1182\/bloodadvances.2017015461.","journal-title":"Blood Adv"},{"key":"826_CR46","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.jval.2022.04.001","volume":"25","author":"N Alrawashdh","year":"2022","unstructured":"Alrawashdh N, McBride A, Erstad B, Sweasy J, Persky DO, Abraham I. Cost-effectiveness and economic burden analyses on all first-line treatments of chronic lymphocytic leukemia. Value Health. 2022;25:1685\u201395. https:\/\/doi.org\/10.1016\/j.jval.2022.04.001.","journal-title":"Value Health."},{"key":"826_CR47","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40273-017-0519-z","volume":"35","author":"J Buchanan","year":"2017","unstructured":"Buchanan J, Wordsworth S, Clifford R, Robbe P, Taylor JC, Schuh A, et al. Using genomic information to guide ibrutinib treatment decisions in chronic lymphocytic leukaemia: a cost-effectiveness analysis. Pharmacoeconomics. 2017;35:845\u201358. https:\/\/doi.org\/10.1007\/s40273-017-0519-z.","journal-title":"Pharmacoeconomics"},{"key":"826_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40265-021-01657-0","volume":"82","author":"LE Roeker","year":"2022","unstructured":"Roeker LE, Thompson M, Mato AR. Current treatment of chronic lymphocytic leukemia: the diminishing role of chemoimmunotherapy. Drugs. 2022;82:133\u201343. https:\/\/doi.org\/10.1007\/s40265-021-01657-0.","journal-title":"Drugs"},{"key":"826_CR49","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40271-020-00430-x","volume":"13","author":"P Lorgelly","year":"2020","unstructured":"Lorgelly P, Pollard J, Cubi-Molla P, Cole A, Sim D, Sussex J. Outcome-based payment schemes: what outcomes do patients with cancer value? Patient. 2020;13:599\u2013610. https:\/\/doi.org\/10.1007\/s40271-020-00430-x.","journal-title":"Patient"},{"key":"826_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.780085","author":"L van der Straten","year":"2021","unstructured":"van der Straten L, Hengeveld PJ, Kater AP, Langerak AW, Levin M-D. Treatment approaches to chronic lymphocytic leukemia with high-risk molecular features. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.780085.","journal-title":"Front Oncol"},{"key":"826_CR51","unstructured":"Pharmaceutical Benefit Schedule. Venetoclax: pack containing 14 tablets venetoclax 10 mg and 7 tablets venetoclax 50 mg and 7 tablets venetoclax 100 mg and 14 tablets venetoclax 100 mg, tablet 10 mg, tablet 50 mg, tablet 100 mg; Venclexta\u00ae. 2020. https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2020-07\/venetoclax-pack-containing-14-tablets-venetoclax-10-mg. Accessed 28 Feb 2023."},{"key":"826_CR52","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1200\/OP.21.00258","volume":"18","author":"EA Brem","year":"2021","unstructured":"Brem EA, O\u2019Brien S. Frontline management of CLL in 2021. J Oncol Pract. 2021;18:109\u201313. https:\/\/doi.org\/10.1200\/OP.21.00258.","journal-title":"J Oncol Pract"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-023-00826-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-023-00826-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-023-00826-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T15:34:53Z","timestamp":1704209693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-023-00826-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["826"],"URL":"https:\/\/doi.org\/10.1007\/s40258-023-00826-4","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"type":"print","value":"1175-5652"},{"type":"electronic","value":"1179-1896"}],"subject":[],"published":{"date-parts":[[2023,8,22]]},"assertion":[{"value":"26 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MV received a PhD (independent) scholarship from Illumina under the University of Melbourne\/Illumina partnership.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The model inputs used to inform the decision analytic model and execute the cost-effectiveness analysis are included within the article with appropriate citations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication from patients\/participants"}},{"value":"The custom codes for the model are available from the corresponding author upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. MV developed the economic model under supervision of KD. The initial draft of the manuscript was written by MV, and critically reviewed for scientific content by all other authors. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}